ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 ...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in ...
Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...
Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.
Pharmaceutical Technology on MSN
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.
() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...
Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback